{"commentary":{"count":36,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":21,"podcast":13,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01523171\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"JAKARTA2","nct_id":"NCT01523171","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=jakarta2-nct01523171. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"JAKARTA2","arms":[{"description":"once daily in consecutive 28-day cycles, flexible dosing regimen (the starting dose is 400mg/day), orally, empty stomach, approximately same time each day","label":"SAR302503 400 mg","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2014-04-30","type":"ACTUAL"},"conditions":["Hematopoietic Neoplasm"],"enrollment":{"count":97,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"SAR302503","type":"DRUG"}],"last_update":"2026-07-16","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated With Ruxolitinib and With a Current Diagnosis of Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2014-04-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Response Rate: Percentage of Participants With >=35% Reduction From Baseline in Spleen Volume at End of Cycle 6","timeFrame":"Baseline, End of Cycle 6"}],"references":[{"citation":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.","pmid":"28602585","type":"DERIVED"}],"start_date":{"date":"2012-04-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib","url":"https://clinicaltrials.gov/study/NCT01523171"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/jakarta2-nct01523171"}